anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to a technology using oriental medicines or medicinal herbs for preventing or treating atopic dermatitis and, more specifically, to a composition prepared with a mixture comprising extracts from Lithospermum erythrorhizom Sieb. et Zucc. Lonicerae Flos, Sophora flavescens Aiton, Duchesnea indica (Andr.) Focke, Artemisia iwayomogi, Lonicera japonica, Phellodendri Cortex and licorice roots for preventing or treating atopic dermatitis. The present invention provides a composition for preventing or treating atopic dermatitis, comprising a mixture of extracts from Lithospermum erythrorhizom Sieb. et Zucc., Lonicerae Flos, Sophora flavescens Aiton, Duchesnea indica (Andr.) Focke, Artemisia iwayomogi, Lonicera japonica, Phellodendri Cortex and licorice roots. Additionally, the present invention provides a composition for preventing or treating atopic dermatitis, which comprises a mixture of 100 parts by weight of a Lithospermum erythrorhizom Sieb. et Zucc. extract, 80-20 parts by weight of a Lonicerae Flos extract, 80-120 parts by weight of a Sophora flavescens Aiton extract, 60-80 parts by weight of a Duchesnea indica (Andr.) Focke extract, 60-80 parts by weight of an Artemisia iwayomogi extract, 60-80 parts by weight of a Lonicera japonica extract, 20-40 parts by weight of a Phellodendri Cortex extract and 10-20 parts by weight of a licorice root extract. Furthermore,the present invention provides a pharmaceutical composition including the composition for preventing or treating atopic dermatitis.
The present invention provides a method for stachyose hydrate extraction. Leaf bamboo shoot or Yintiao are cleaned, grinded and soaked, and then are Paste-pasteurized. The plant protein of the leaf bamboo shoot or Yintiao is coagulated. The fruit compound enzyme which is ten thousandth of the weight of the extraction is added into the extraction for degumming. After the degumming, the solution is filtered by 10000D ultrafiltration membrane, and then is bleached and concentrated in vacuum, and is dried into stachyose hydrate powders. The method solves the problem of the use of chemical reagents which generates lead salt residue. The method shortens the processing time. The production rate of the method is more than 90 percent and the purity is of 95 percent. Raw materials utilization in the method is high.
This is a randomized, double-blind, placebo-controlled study. subjects will be randomized to receive investigational vaccine or placebo at a ratio of 3.5:1, MVA3000 to placebo. All subjects will undergo a screening period, a treatment/observation period during which all subjects will receive injections on study day 0 and study day 28 of investigational vaccine or placebo. The clinical observation period will be completed at day 56. A visit will occur at approximately 3 months after the second study injection (study day 118) for additional blood collection and a review of the subject's health status. Follow-up will be obtained via telephone contacts approximately 6 months after the end of the second injection during the treatment/observation period.
The present invention discloses a medicine for treating fatty liver, which is prepared from 85 to 100 weight portions of milkvetch root, 70 to 95 weight portions of largehead atractylodes rhizome, 70 to 95 weight portions of atractylodes rhizome, 80 to 100 weight portions of water plantain, 70 to 95 weight portions of polyporus, 70 to 90 weight portions of tuckahoe, 60 to 75 weight portions of rhubarb, 60 to 80 weight portions of weeping forsythia capsule, 45 to 60 weight portions of common prism tuber, 45 to 60 weight portions of zedoray rhizome, 65 to 80 weight portions of hawthorn fruit, 55 to 70 weight portions of lotus leaf and 45 to 60 weight portions of cassia bark. The effective rate of the medicine of the present invention is 97%, the healing rate is 66%, and the effective rate and the healing rate of the medicine of the present invention are obviously improved higher than that of the existing medicines. The medicines for treating both manifestation and root causes of diseases are selected, the medicines are selected to treat root causes of diseases according to the traditional Chinese medicine theory, and the medicines are selected to treat manifestation causes of diseases according to the modern medicine theory. The medicine of the present invention pays attention to strengthening healthy qi, and positive strong evil is automatically eliminated. The medicine properties are soft, the adopted medicines are agents for gradually disappearing and slowly dispersing, and the medicine effect is slowly penetrated into the disease evil. The medicine of the present invention has the advantages of no toxic or side effect, no disadvantages when the medicine is taken for a long term, high safety, reliability, simple preparation, low cost, convenient administration, portability and convenient popularization.
Methylphenidate 60 mg. po will be given 60 minutes prior to \[11C\]raclopride scan to measure striatal dopamine release. MRI scan to follow end of PET scan. Subject blind as to drug administration.
The study was performed with 11 healthy sportsmen participating in a caloric restriction trial for 1 month. The participants follow a caloric restriction, 30-40% respect to the usual diet of each participant, three alternate days weekly along 4 weeks. After the caloric restriction period the participants realized an exercise stress test. For each participant one blood sample and muscular biopsy were obtained after acute exercise and caloric restriction intervention. All the participants were informed of the purpose and demands of the study before giving their written consent to participate. The study protocol was in accordance with the Declaration of Helsinki for research on human participants and was approved by the local Ethics Committee of the Consell Català de l'Esport.
Participants (50 children and 50 young adults) will be submitted to two conditions of virtual experience, one condition in which it is possible to interact with the stimuli presented in the virtual environment and another condition in which it is not possible to interact. In addition, the stimuli of interest will be of one of three emotional categories : negative, positive and neutral. Thus participants will be exposed to six short virtual experiences.
Process of obtaining lycopene. The present invention relates to a new process of obtaining carotenoids, especially lycopene, starting from natural biosynthesis sources in general and, specifically, from submerged cultures of mucorales fungi such as Blakeslea, Choanephora or Phycomyces. The process described makes it possible to simplify the recovery process and obtain an increase in purity of the product. It comprises the following steps:   1) Direct treatment with alcohol on the natural source of biosynthesis (fermentation medium for example) and separation of a wet, purified biomass. 2) Conditioning of the purified biomass by drying plus disintegration or breakdown of the same. 3) Solid-liquid extraction of the lycopene with an organic solvent.    4) Concentration of the enriched extract.   5) Precipitation/crystallization by addition of alcohol.   6) Filtration. 7) Dryingin
All subjects will be given diacerein with a starting dose of 50 mg in one tablet once daily for 2 weeks. After 2 weeks, they will be given diacerein 50 mg in one tablet twice daily for the duration of sudy.
The present invention provides methods which permit animal owners or animal food producers to readily establish the vaccination status of animals. More specifically, the present invention provides a method for identifying an animal that has been vaccinated with an immunogen by forming a vaccine composition which includes the immunogen and a recombinant, substantially non-toxic mutant of E. coli heat labile enterotoxin (rmLT); administering the vaccine composition to animal subjects; and detecting the presence of antibodies or immune cells in an animal that are specific for the rmLT as indicative of an earlier vaccination of the animal with the immunogen. The present invention also provides a method for determining whether an animal has been vaccinated with a vaccine composition which includes an immunogen and a substantially non-toxic rmLT by detecting the presence of antibodies or immune cells in an animal that are specific for the rmLT as indicative of an earlier vaccination of the animal with the immunogen. Furthermore, the present invention provides a method for marking or identifying a vaccine composition by including in the vaccine composition a substantially non-toxic rmLT and detecting the presence of antibodies or immune cells in animals administered with such vaccine composition. Moreover, the present invention provides a method for enhancing the immunoprotective effects of an immunogen in a vaccine composition by including in the vaccine composition a substantially non-toxic rmLT. Vaccine compositions containing an immunogen, a substantially non-toxic rmLT and an oil-in- water emulsion adjuvant such as AMPHIGEN, are also provided.
This study assesses the feasibility of calorie restriction (CR) and time-restricted feeding (TRF) in overweight and obese cancer patients who realized little to no physical activity undergoing curative radiotherapy, structured as a prospective, interventional, non-randomized open-label clinical trial. Of the 27 participants initially enrolled, 21 patients with breast cancer were selected for analysis. The participants self-selected into two dietary interventions: TRF, comprising a sugar and saturated fat-free diet calibrated to individual energy needs consumed within an 8 h eating window followed by a 16 h fast, or CR, involving a 25% reduction in total caloric intake from energy expenditure distributed across 4 meals and 1 snack with 55% carbohydrates, 15% protein, and 30% fats, excluding sugars and saturated fats. The primary goal was to evaluate the feasibility of these diets in the specific patient group. The results indicate that both interventions are effective and statistically significant for weight loss and reducing one's waist circumference, with TRF showing a potentially stronger impact and better adherence. Changes in the LDL, HDL, total cholesterol, triglycerides, glucose and insulin were not statistically significant.
Critically ill children at participating centers who require select vital organ support measure (i.e. mechanical ventilation, vasopressor, or continuous renal replacement therapy) will have routine blood glucose (BG) screening initiated (i.e. at least q 12 hours). If a patient has a BG reading of \> 140 mg/dL, a repeat BG will be obtained in 1-2 hours. If this second BG is \> 140 mg/dL the patient will be diagnosed with critical illness hyperglycemia and an insulin infusion will be started and BG will be maintained between 80-140 using a pediatric specific developed and tested algorithm.
Patients diagnosed with Irritable bowel syndrome who will follow diet restrictions for 28 days. After the first month the patients are crossed between groups.
PRCIS: This study showed that the XEN patency should be verified by OCT imaging in cases of encapsulated blebs. Although fibrosis plays the principal role, humor aqueous flow reduction could affect the "spacer" effect that inhibits the fibroblast attachments.
PURPOSE: To evaluate the application of the anterior segment optical coherence tomography (AS-OCT) imaging in studying the relationship between a low flow rate through the XEN63 and the development of a cystic bleb.
METHODS: Retrospective case series of 3 eyes presenting a cystic bleb after an XEN63 implantation for uncontrolled intraocular pressure (IOP). Demographic and clinical data were obtained from medical records. The imaging findings, complications, and managements following the surgery were evaluated.
RESULTS: Three patients, with an average age of 67.3 years, initially showed a patent stent lumen and a functional bleb after surgery. The IOP of all eyes increased on average at 28.3 days from the surgery, with a mean value of 39.66 mm Hg. The slit lamp examination showed a cystic bleb. The AS-OCT imaging confirmed the previous finding and revealed either a partial or total occlusion of the stent internal ostium. A Nd:YAG laser, in proximity to the ostium, was performed to resolve the obstruction. Although the AS-OCT imaging showed the device patency and the IOP immediately decreased, the latter became elevated again. Consequently, in all the cases, a further needling procedure was needed to achieve an adequate IOP reduction. Six months after the two-step procedure, the IOP averaged 13.33 mm Hg, the XEN63 lumens appeared cleared, and the blebs showed a functional morphology. No adverse events were observed.
CONCLUSION: The development of a cystic bleb may result from an altered balance between the flow rate through the XEN63 and the fibrosis development in the postoperative healing process. A proper follow-up based on slit lamp biomicroscopy, IOP measurement, and AS-OCT imaging is advisable to estimate and manage a cystic bleb following XEN63 implantation.
Participants will receive 12 weeks of induction therapy with PEG-IFN alfa-2a (Pegasys), 360 micrograms (mcg) subcutaneous (SC) once weekly, along with ribavirin, 1000 or 1200 milligrams (mg) orally daily in divided doses. Thereafter, the dose of PEG-IFN alfa-2a will be reduced to 180 mcg SC once weekly and the ribavirin dose maintained for the remaining 36 weeks of treatment.
The purpose of this study is to determine if treatment with stereotactic body radiotherapy (SBRT) on non-consecutive days will improve the chance of curing non-small cell lung cancer compared to treatment with SBRT on consecutive days. In either case, the dose of radiation is the same. Non-consecutive treatments will be at least 40 hours apart and no more than 100 hours apart. The total course of treatment will be 8-12 days. Consecutive treatments will be daily over 4-5 days within one calendar week. The total course of treatment will be 4-5 days.

The study team will assess if DNA from the tumor can be found in the blood to determine which patients respond quickest to radiotherapy. These results will not be made available to participants and will not change treatment.
Human genetic evidence suggests a protective role of loss-of-function variants in 17-beta hydroxysteroid dehydrogenase 13 (HSD17B13) for liver fibrotic diseases. Although there is limited preclinical experimental data on Hsd17b13 antisense oligonucleotide (ASO) or siRNA in a fibrosis model, several ASO and siRNA approaches are being tested clinically as potential therapies for nonalcoholic steatohepatitis (NASH). The aim of this study was to assess the therapeutic potential of Hsd17b13 ASO in a preclinical advanced NASH-like hepatic fibrosis in vivo model. In vitro testing on primary hepatocytes demonstrated that Hsd17b13 ASO exhibited strong efficacy and specificity for knockdown of the Hsd17b13 gene. In choline-deficient, L-amino acid-defined, HFD (CDAHFD)-induced steatotic and fibrotic mice, therapeutic administration of Hsd17b13 ASO resulted in a significant and dose-dependent reduction of hepatic Hsd17b13 gene expression. The CDAHFD group exhibited considerably elevated liver enzyme levels, hepatic steatosis score, hepatic fibrosis, and increased fibrotic and inflammatory gene expression, indicating an advanced NASH-like hepatic fibrosis phenotype. Although Hsd17b13 ASO therapy significantly affected hepatic steatosis, it had no effect on hepatic fibrosis. Our findings demonstrate, for the first time, that Hsd17b13 ASO effectively suppressed Hsd17b13 gene expression both in vitro and in vivo, and had a modulatory effect on hepatic steatosis in mice, but did not affect fibrosis in the CDAHFD mouse model of NASH.
Patients who choose operations will have surgery performed to remove the appendix laparoscopically, through 3 or 4 small incisions. All patients in the operative group will receive standard perioperative antibiotics. They will also have the abscess(es) drained during the same surgery if there is one present. In some cases, the operation may be too difficult to perform laparoscopically, so an open appendectomy will be performed, involving a longer incision to remove the appendix. In some cases, both laparoscopic and open are performed. The surgeon may also choose to remove a section of the intestine with the appendix or perform additional procedures.
BACKGROUND AND AIMS: Whether the natural course of ulcerative colitis (UC) in mainland China is similar or different from that in Western countries is unknown, and data on it is limited. We aimed to provide a comprehensive description of the natural course of UC in China and compare it with Western UC patients.
METHODS: Based on a prospective Chinese nationwide registry of consecutive patients with inflammatory bowel diseases, the medical treatments and natural history of UC were described in detail, including disease extension, surgery, and neoplasia. The Cox regression model was used to identify factors associated with poor outcomes.
RESULTS: A total of 1081 UC patients were included with a median follow-up duration of 5.3 years. The overall cumulative exposure was 99.1% to 5-aminosalicylic acids, 52.1% to corticosteroids, 25.6% to immunomodulators, and 15.4% to biologics. Disease extent at diagnosis was proctitis in 26.9%, left-sided colitis in 34.8%, and extensive colitis in 38.3%. Of 667 patients with proctitis and left-sided colitis, 380 (57.0%) experienced disease extent progression. A total of 58 (5.4%) UC patients underwent colectomy, demonstrating cumulative proportions of surgery at 1, 5, and 10 years after diagnosis of 0.6%, 3.4%, and 8.2%, respectively. In addition, 23 (2.1%) UC patients were diagnosed with neoplasia, demonstrating cumulative proportions of neoplasia at 1, 5, and 10 years after diagnosis of 0.5%, 1.0%, and 3.5%, respectively.
CONCLUSIONS: Chinese UC patients had similar cumulative proportions of exposure to IBD-specific treatments but a lower surgical rate than patients in Western countries, indicating a different natural course, and close monitoring needs for UC in China. However, these results must be confirmed in population-based studies because the hospital-based cohort in our study might lead to selection bias.
Vitamin-like substances which are probably flavanone glucosides are obtained from plant materials such as lemon and orange peel by first extracting with a water-miscible organic solvent such as alcohol or acetone, precipitating the flavanone derivative by adding an alkali or alkaline earth hydroxide, and decomposing the precipitate by means of an acid.  The precipitate may be suspended in an organic water-miscible solvent and decomposed with an acid such as carbonic acid, the flavanone derivative going into solution while the inorganic salt separates, or the precipitate may be treated with acid in an aqueous solution.  The crude solution obtained from the plant-material may be preliminarily purified by adding a heavy metal salt in an acid medium (such as lead acetate) the precipitate being discarded, and then rendering the solution alkaline, for instance by adding ammonia, whereby the heavy metal compound of the flavanone is precipitated.  This precipitate is suspended in water or alcohol and decomposed by an acid; in the former case the solution after separating the inorganic compound is concentrated and organic solvent is added to precipitate the impurities, after which the flavanone is precipitated by alkali as described above; in the latter case the alcoholic solution is precipitated in this manner. In examples, (1) comminuted lemon peel is extracted with 90 per cent alcohol, lead acetate is added, the precipitate is removed, and ammonia is added; the precipitate is suspended in 5 per cent acetic acid, neutralized with ammonia, and the precipitate suspended in absolute alcohol and decomposed with sulphuric acid the precipitate being discarded; the solution is neutralized with alcoholic soda and the precipitate is dissolved in water and alcohol is added, a resinous precipitate being separated; the resinous precipitate is dissolved in water, neutralized, and alcohol is added, the precipitate being separated; the remaining solution, together with that separated from the resinous precipitate, is cooled to -15 DEG  C. and alcoholic caustic soda is added to give a strong red colour with phenolphthalein the precipitate is separated, dissolved in N hydrochloric acid, and bicarbonate is added; a part of the flavanone separates as eriodictyol glucoside and hesperidin, and the remaining solution of eriodictyol glucoside is adjusted, filtered, and filled into ampoules; a further quantity of eriodictyol glucoside may be obtained from the precipitate separated at -15 DEG  C. by dissolving in water, precipitating with alcohol, and proceeding as described above; (2) bitter orange peel freed from the yellow layer, is comminuted and extracted with absolute alcohol and the extract is cooled and precipitated with alcoholic soda as in the later steps of example 1, that is without the lead acetate treatment.  The Provisional Specification mentions capsicum as an initial material, and describes a purification treatment in which a second addition of lead acetate is made after the neutralization of the solution from the first addition.
The patients were divided into two equal group of thirty patients in each group; Control group (normotensive pregnant women) and Mild preeclampsia group. In both groups patients preloaded with 500 mL hydroxyethyl starch (HES) 6% (130/0.4) (Voluven). Spinal anesthesia will be performed with intrathecal 10-12 mg hyperbaric bupivacaine in addition to 200 meg morphine. The patient was placed supine with left lateral tilt to alleviate aortocaval compression. 10 ml/kg of isotonic 0.9 sodium chloride (NaCl) solutions will be used co loading during the duration of the operation. Blood pressure was measured and recorded every three minutes. If severe hypotension (fall of \> 20% of mean arterial pressure from baseline) occurred, vasopressors, 6 mg ephedrine (per dose) will be used. The blood pressure will rechecked 1 minute after each doses of ephedrine. If hypotension persisted after 30 mg of ephedrine, an additional 2 ml/kg of isotonic 0.9 NaCl solutions will be infused rapidly. Maternal hypotension is defined as at least a single administration of ephedrine within the period from induction of spinal anesthesia until transfer to postoperative recovery unit. Reactive hypertension is characterized as a blood pressure 20% greater than baseline mean levels after the use of the vasopressor. Bradycardia is defined as a fall of \>30% of heart rate from baseline or \<50 beats /minute. Bradycardia, and when associated with hypotension it will be treated with 0.5 mg of atropine intravenous. Upon completion of the cesarean section, the subject will be transported to the postanesthesia care unit (PACU).